The Experts below are selected from a list of 10686 Experts worldwide ranked by ideXlab platform
Frederick T Short - One of the best experts on this subject based on the ideXlab platform.
-
labyrinthula Zosterae sp nov the causative agent of wasting disease of eelgrass Zostera marina
Mycologia, 1991Co-Authors: Lisa K Muehlstein, David Porter, Frederick T ShortAbstract:A pathogenic species of marine slime mold, Labyrinthula, has been identified as the etiological agent ofthe present recurrence of wasting disease of eelgrass, Zostera marina. It is also implicated as causing the previous epidemic eelgrass wasting disease that occurred in the 1930s. We propose Labyrinthula Zosterae sp. nov. for this pathogen based on its host specificity, cytology, characteristic growth patterns in culture, cell size, color in mass, and aggregation structures.
-
Zostera: Biology, Ecology, and Management
SEAGRASSES: BIOLOGY ECOLOGYAND CONSERVATION, 1Co-Authors: Kenneth A. Moore, Frederick T ShortAbstract:The nine species comprising the genus Zostera discussed in this chapter form a widespread and relatively well-studied group of seagrasses. Some of the earliest studies of seagrasses occurred within the genus Zostera, especially the extensively researched Zostera marina L. (Petersen, 1890, 1918). The proximity of this species to industrialized areas and centers of scientific investigation in North America, Europe, and Asia has encouraged a continued scientific focus. Like all seagrasses, those of the genus Zostera live in intertidal and subtidal inshore waters, forming a critical habitat and a basis of the food web. Study of the genus Zostera is itself representative of trends in seagrass science, with PAM fluorometry assessments of photosynthesis and genetic investigations among the newer efforts. We here review the current knowledge of this important genus, although space constraints do not allow exhaustive coverage of all past and current Zostera research. We also point to future research directions.
Nancy Lang - One of the best experts on this subject based on the ideXlab platform.
-
immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella zoster virus vaccine an exploratory randomised partly blinded trial
Lancet Infectious Diseases, 2016Co-Authors: Chan R Beals, Radha Railkar, Andrea K Schaeffer, Yotam Levin, Efrat Kochba, Brian K Meyer, Robert K Evans, Eric A Sheldon, Kenneth C Lasseter, Nancy LangAbstract:Summary Background The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years. We aimed to determine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle subcutaneous administration. Methods In this randomised, dose-ranging study, adults aged 50 years or older who had a history of varicella or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more were eligible. Participants received the approved full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intradermal doses (full, 1/3, 1/10, or 1/27 dose) using the MicronJet600 device. The two subcutaneous doses and the four intradermal doses were randomised (1·5:1:1:1:1:1) by computer generated sequence with randomisation stratified by age (50–59 years or 60 years or older). The primary immunogenicity endpoint was the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA) measured at 6 weeks. All patients were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, number NCT01385566. Findings Between Sept 2, 2011, and Jan 13, 2012, 224 participants were enrolled from three clinics in the USA and 223 were randomly assigned: 52 to receive the full dose subcutaneous zoster vaccine, 34 to receive the 1/3 dose subcutaneous zoster vaccine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 dose intradermal zoster vaccine. Full dose zoster vaccine given subcutaneously resulted in a gpELISA geometric mean fold-rise (GMFR) of 1·74 (90% CI 1·48–2·04) at 6 weeks post-vaccination compared with intradermal administration which resulted in a significantly higher gpELISA GMFR of 3·25 (2·68–3·94; p Interpretation Intradermal zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses. Larger and longer studies of intradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence of improved cell mediated immunity. Funding Merck & Co Inc.
Lisa K Muehlstein - One of the best experts on this subject based on the ideXlab platform.
-
labyrinthula Zosterae sp nov the causative agent of wasting disease of eelgrass Zostera marina
Mycologia, 1991Co-Authors: Lisa K Muehlstein, David Porter, Frederick T ShortAbstract:A pathogenic species of marine slime mold, Labyrinthula, has been identified as the etiological agent ofthe present recurrence of wasting disease of eelgrass, Zostera marina. It is also implicated as causing the previous epidemic eelgrass wasting disease that occurred in the 1930s. We propose Labyrinthula Zosterae sp. nov. for this pathogen based on its host specificity, cytology, characteristic growth patterns in culture, cell size, color in mass, and aggregation structures.
Chan R Beals - One of the best experts on this subject based on the ideXlab platform.
-
immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella zoster virus vaccine an exploratory randomised partly blinded trial
Lancet Infectious Diseases, 2016Co-Authors: Chan R Beals, Radha Railkar, Andrea K Schaeffer, Yotam Levin, Efrat Kochba, Brian K Meyer, Robert K Evans, Eric A Sheldon, Kenneth C Lasseter, Nancy LangAbstract:Summary Background The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years. We aimed to determine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle subcutaneous administration. Methods In this randomised, dose-ranging study, adults aged 50 years or older who had a history of varicella or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more were eligible. Participants received the approved full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intradermal doses (full, 1/3, 1/10, or 1/27 dose) using the MicronJet600 device. The two subcutaneous doses and the four intradermal doses were randomised (1·5:1:1:1:1:1) by computer generated sequence with randomisation stratified by age (50–59 years or 60 years or older). The primary immunogenicity endpoint was the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA) measured at 6 weeks. All patients were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, number NCT01385566. Findings Between Sept 2, 2011, and Jan 13, 2012, 224 participants were enrolled from three clinics in the USA and 223 were randomly assigned: 52 to receive the full dose subcutaneous zoster vaccine, 34 to receive the 1/3 dose subcutaneous zoster vaccine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 dose intradermal zoster vaccine. Full dose zoster vaccine given subcutaneously resulted in a gpELISA geometric mean fold-rise (GMFR) of 1·74 (90% CI 1·48–2·04) at 6 weeks post-vaccination compared with intradermal administration which resulted in a significantly higher gpELISA GMFR of 3·25 (2·68–3·94; p Interpretation Intradermal zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses. Larger and longer studies of intradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence of improved cell mediated immunity. Funding Merck & Co Inc.
Andy Anderson - One of the best experts on this subject based on the ideXlab platform.
-
Meningoencephalitis-complicating herpes zoster ophthalmicus infection†
Journal of Hospital Medicine, 2009Co-Authors: Saranya Srinivasan, Andy AndersonAbstract:Herpes zoster ophthalmicus is a known complication of herpes zoster and the most common manifestation of cranial zoster, accounting for a significant number of zoster cases.1 An uncommon but serious complication of herpes zoster ophthalmicus is zoster meningoencephalitis. The exact incidence of herpes zoster meningoencephalitis is not known; in 1 series, 5.5% of patients who initially presented with ophthalmic zoster had neurological complications.2 Here we report a case of herpes zoster meningoencephalitis in a patient with herpes zoster ophthalmicus. Journal of Hospital Medicine 2009;4:E19–E22. © 2009 Society of Hospital Medicine.